Alnylam Pharmaceuticals, Inc. (ALNY) on Focus After Forming Bullish Double Top Chart Pattern

December 7, 2017 - By Winifred Garcia

Investors sentiment increased to 1.52 in 2017 Q2. Its up 0.70, from 0.82 in 2017Q1. It improved, as 24 investors sold Alnylam Pharmaceuticals, Inc. shares while 49 reduced holdings. 49 funds opened positions while 62 raised stakes. 85.40 million shares or 6.40% more from 80.26 million shares in 2017Q1 were reported.
Great West Life Assurance Com Can holds 0% or 8,209 shares in its portfolio. Winslow Evans And Crocker has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Ubs Asset Mgmt Americas holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 1.45M shares. Sphera Funds Limited stated it has 0.68% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Van Eck reported 0.06% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Comerica Bancorp has invested 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Bank Of Ny Mellon Corp accumulated 333,942 shares. Qs owns 2,408 shares. Arrowmark Colorado Ltd Liability holds 0.53% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 538,289 shares. Tiaa Cref Inv Management Ltd has 508,852 shares. State Street Corporation invested 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Metropolitan Life New York invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Cormorant Asset Ltd Llc accumulated 125,000 shares. Natixis Asset Mgmt owns 15,072 shares. Rhenman And Prtn Asset Mngmt Ab holds 0.92% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 80,190 shares.

The chart of Alnylam Pharmaceuticals, Inc. (ALNY) shows a double top with $139.03 target or 8.00 % above today’s $128.73 share price. The 5 months chart pattern indicates low risk for the $12.77B company. It was reported on Dec, 7 by Finviz.com. If the $139.03 price target is reached, the company will be worth $1.02B more. Double tops are rare but powerful chart patterns.

The stock increased 3.34% or $4.16 during the last trading session, reaching $128.73. About 754,726 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since December 7, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 14. They expect $-1.36 earnings per share, down 3.03 % or $0.04 from last year’s $-1.32 per share. After $-1.34 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.49 % negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 84 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Wednesday, November 8 by BMO Capital Markets. As per Friday, July 7, the company rating was maintained by Chardan Capital Markets. As per Thursday, October 6, the company rating was downgraded by JP Morgan. Piper Jaffray maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, September 7. Piper Jaffray has “Buy” rating and $110.0 target. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Monday, June 26 by Cowen & Co. On Wednesday, November 16 the stock rating was maintained by Needham with “Buy”. As per Thursday, February 9, the company rating was maintained by Needham. The rating was maintained by Credit Suisse with “Outperform” on Friday, November 3. The firm has “Buy” rating by Chardan Capital Markets given on Monday, June 12. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Friday, November 17 by Piper Jaffray.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Nasdaq.com which released: “Commit To Buy Alnylam Pharmaceuticals At $70, Earn 11.4% Using Options” on November 28, 2017, also Fool.com with their article: “Why Alnylam Pharmaceuticals Rose 12.7% in November” published on December 06, 2017, Seekingalpha.com published: “Alnylam Pharmaceuticals (ALNY) Q3 2017 Results – Earnings Call Transcript” on November 08, 2017. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Alnylam Sets Its Eyes On The Finish Line” published on November 20, 2017 as well as Fool.com‘s news article titled: “Alnylam Pharmaceuticals, Inc.’s Pipeline Progresses, Approval Next” with publication date: November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.